Save Product
Product Details
Materials Provided
IDComponentsSizeEP168-C01High-bind Plate1 plateEP168-C02Human DR3100 μgEP168-C03Human TL1A-SABC5 μgEP168-C04Human Anti-TL1A Neutralizing Antibody100 μgEP168-C05Coating Buffer12 mLEP168-C0620xWashing Buffer50 mLEP168-C07Blocking Buffer50 mLEP168-C08Substrate Solution12 mLEP168-C09Stop Solution7 mLProduct Overview
TL1A [Biotinylated] : DR3 Inhibitor Screening ELISA Kit is based on a competition-ELISA method, is used to screening for inhibitors of human TL1A binding to human DR3. The kit is designed to provide a reliable solution for the screening of antibodies and small molecule inhibitors in the early stages, as well as QC release, to help researchers quickly screen and validate drugs, effectively improving research and development efficiency. It can also be used as a universal detection tool to identify the ability of human TL1A binding to human DR3.
Reconstitution
Please see Certificate of Analysis for details of reconstitution instruction and specific concentration.
Storage
Unopened kit should be stored at 2°C -8°C upon receiving. Find the expiration date on the outside packaging and do not use reagents past their expiration date.
The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.
ACRO Quality Management System
Customers Also Viewed
Performance Data
Typical Data
Please refer to DS document for the assay protocol.
Serial dilutions of Human Anti-TL1A Neutralizing antibody (Catalog # EP168-C04) (1:1 serial dilution, from 5 μg/mL to0.0390625 μg/mL) was added into Human DR3 : Biotinylated Human TL1A binding reactions. The assay was performed according to the protocol described below. Background was subtracted from data points prior to log transformation and curve fitting (QC tested).
For each experiment, a standard curve needs to be set for each micro-plate, and the specific OD value may vary depending on different laboratories, testers, or equipments. The example data is for reference only.
Customer Reviews Writing Reviews
Recent Advances
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
